We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ABIOMED (ABMD) Q1 Earnings Top Estimates, Sales Rise in Japan
Read MoreHide Full Article
ABIOMED, Inc. reported first-quarter fiscal 2020 earnings per share (EPS) of $1, which beat the Zacks Consensus Estimate by a penny. The figure rose 28.2% year over year.
The Zacks Rank #4 (Sell) company’s revenues came in at $207.7 million, missing the Zacks Consensus Estimate of $210.6 million. However, the metric improved 15.4% from the prior-year quarter.
Fiscal Q1 in Detail
Worldwide Impella heart pump revenues in the reported quarter totaled $199.9 million, reflecting an increase of 15% year over year. U.S. Impella product revenues totaled $168.3 million, an increase of 11% year over year. Per management, U.S. patient usage of the Impella heart pumps rose 13% in the quarter.
Outside the United States, Impella product revenues totaled $31.5 million, highlighting an increase of 44% year over year. Japan revenues were $8.5 million in the quarter, up a substantial 227% year over year.
In the quarter under review, gross profit totaled $170.6 million, up 14.4% year over year. Gross margin in the quarter was 82.1% of net revenues, down 80 basis points (bps) year over year. Research & Development (R&D) costs grossed $23.8 million, up 11.8% year over year.
Operating income totaled $60.7 million, up 30% on a year-over-year basis. Operating margin was 29.2%, up 320 bps.
Financial Condition
ABIOMED’s balance sheet remains debt free. The company ended the fiscal first quarter with $526.7 million of cash and marketable securities.
Guidance Slashed
For fiscal 2020, ABIOMED expects total revenues in the range of $885-$925 million, an increase of 15% to 20% year over year. This range is below the earlier provided guidance range of $900-$945 million, calling for a year-over-year increase of 17-23%. The Zacks Consensus Estimate for the same stands at $925.3 million, slightly above the projected range.
Summing Up
ABIOMED exited the fiscal first quarter on a mixed note. The company continues to gain from its flagship Impella, which saw a strong quarter. Impella’s patient success stories and increasing global adoptions are added positives. Revenues from Japan skyrocketed in the quarter. Considerable expansion in the operating margin buoys optimism. Meanwhile, surging R&D expenses show increasing focus on innovation. Recent product launches and regulatory approvals buoy optimism. Considerable expansion in operating margin is a positive.
On the flip side, the drop in gross margin is disheartening. A slashed guidance for fiscal 2020 adds to the woes.
Earnings of Other MedTech Majors at a Glance
Some better-ranked stocks, which posted solid results this earnings season, are Stryker Corporation (SYK - Free Report) , Baxter International Inc. (BAX - Free Report) and Intuitive Surgical, Inc. (ISRG - Free Report) .
Stryker delivered second-quarter 2019 adjusted EPS of $1.98, beating the Zacks Consensus Estimate by 2.6%. Its revenues of $3.65 billion surpassed the Zacks Consensus Estimate by 1.4%. The company currently carries a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Baxter delivered second-quarter 2019 adjusted EPS of 89 cents, which surpassed the Zacks Consensus Estimate of 81 cents by 9.9%. Its revenues of $2.84 billion outpaced the Zacks Consensus Estimate of $2.79 billion by 1.9%. The company currently has a Zacks Rank #2.
Intuitive Surgical reported second-quarter 2019 adjusted EPS of $3.25, which beat the Zacks Consensus Estimate of $2.85. Its revenues of $1.1 billion surpassed the Zacks Consensus Estimate of $1.03 billion. The company sports a Zacks Rank #1 at present.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
ABIOMED (ABMD) Q1 Earnings Top Estimates, Sales Rise in Japan
ABIOMED, Inc. reported first-quarter fiscal 2020 earnings per share (EPS) of $1, which beat the Zacks Consensus Estimate by a penny. The figure rose 28.2% year over year.
The Zacks Rank #4 (Sell) company’s revenues came in at $207.7 million, missing the Zacks Consensus Estimate of $210.6 million. However, the metric improved 15.4% from the prior-year quarter.
Fiscal Q1 in Detail
Worldwide Impella heart pump revenues in the reported quarter totaled $199.9 million, reflecting an increase of 15% year over year.
U.S. Impella product revenues totaled $168.3 million, an increase of 11% year over year. Per management, U.S. patient usage of the Impella heart pumps rose 13% in the quarter.
Outside the United States, Impella product revenues totaled $31.5 million, highlighting an increase of 44% year over year. Japan revenues were $8.5 million in the quarter, up a substantial 227% year over year.
ABIOMED, Inc. Price, Consensus and EPS Surprise
ABIOMED, Inc. price-consensus-eps-surprise-chart | ABIOMED, Inc. Quote
Margin Trend
In the quarter under review, gross profit totaled $170.6 million, up 14.4% year over year. Gross margin in the quarter was 82.1% of net revenues, down 80 basis points (bps) year over year. Research & Development (R&D) costs grossed $23.8 million, up 11.8% year over year.
Operating income totaled $60.7 million, up 30% on a year-over-year basis. Operating margin was 29.2%, up 320 bps.
Financial Condition
ABIOMED’s balance sheet remains debt free. The company ended the fiscal first quarter with $526.7 million of cash and marketable securities.
Guidance Slashed
For fiscal 2020, ABIOMED expects total revenues in the range of $885-$925 million, an increase of 15% to 20% year over year. This range is below the earlier provided guidance range of $900-$945 million, calling for a year-over-year increase of 17-23%. The Zacks Consensus Estimate for the same stands at $925.3 million, slightly above the projected range.
Summing Up
ABIOMED exited the fiscal first quarter on a mixed note. The company continues to gain from its flagship Impella, which saw a strong quarter. Impella’s patient success stories and increasing global adoptions are added positives. Revenues from Japan skyrocketed in the quarter. Considerable expansion in the operating margin buoys optimism. Meanwhile, surging R&D expenses show increasing focus on innovation. Recent product launches and regulatory approvals buoy optimism. Considerable expansion in operating margin is a positive.
On the flip side, the drop in gross margin is disheartening. A slashed guidance for fiscal 2020 adds to the woes.
Earnings of Other MedTech Majors at a Glance
Some better-ranked stocks, which posted solid results this earnings season, are Stryker Corporation (SYK - Free Report) , Baxter International Inc. (BAX - Free Report) and Intuitive Surgical, Inc. (ISRG - Free Report) .
Stryker delivered second-quarter 2019 adjusted EPS of $1.98, beating the Zacks Consensus Estimate by 2.6%. Its revenues of $3.65 billion surpassed the Zacks Consensus Estimate by 1.4%. The company currently carries a Zacks Rank of 2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Baxter delivered second-quarter 2019 adjusted EPS of 89 cents, which surpassed the Zacks Consensus Estimate of 81 cents by 9.9%. Its revenues of $2.84 billion outpaced the Zacks Consensus Estimate of $2.79 billion by 1.9%. The company currently has a Zacks Rank #2.
Intuitive Surgical reported second-quarter 2019 adjusted EPS of $3.25, which beat the Zacks Consensus Estimate of $2.85. Its revenues of $1.1 billion surpassed the Zacks Consensus Estimate of $1.03 billion. The company sports a Zacks Rank #1 at present.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>